Navigation Links
New Bisphenol A Study Is of Very Limited Relevance to Human Health
Date:6/17/2009

ARLINGTON, Va., June 17 /PRNewswire-USNewswire/ -- The following statement can be attributed to Steven G. Hentges, Ph.D. of the American Chemistry Council's (ACC) Polycarbonate/BPA Global Group. Dr. Hentges' comments are in regard to a study from researchers at North Carolina State University (NCSU) and the National Institute of Environmental Health Sciences (NIEHS). The study, "Neonatal bisphenol A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin releasing hormone neurons," was funded by NIEHS and published online June 17 by the journal Biology of Reproduction. The study was co-authored by Heather B. Patisaul and Heather B. Adewale of NCSU and Wendy N. Jefferson and Retha R. Newbold of NIEHS.

"The American Chemistry Council (ACC) and its member companies have long-supported research to advance scientific understanding about chemicals and promote public health. To achieve these goals with limited resources, including limited use of laboratory animals, study designs should be based on sound scientific principles and data so as to be directly relevant to human health. This new study fails to meet these basic study design principles and practices.

"It is a continuing disappointment to see that researchers -- including scientists from National Institute of Environmental Health Sciences (NIEHS) -- conduct studies that involve injection of laboratory animals with bisphenol A (BPA). This experimental technique has recently been acknowledged by the NIEHS to have very limited value for assessing human health effects since people are orally exposed to BPA, not by injection. It is well-known that BPA is efficiently metabolized and rapidly eliminated from the body after oral exposure.

"The researchers also state, incorrectly, that their study is significant because it used a dose equal to the EPA reference dose for BPA, which is a science-
'/>"/>

SOURCE American Chemistry Council
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Bisphenol A Study Has Limited Capability to Assess Human Health Effects
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014   Rock Creek ... that the Company is scheduled to present at the ... Francisco, CA on January 12-14, 2015. ... and CEO of Rock Creek Pharmaceuticals, will present preclinical ... cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan ...
(Date:11/21/2014)... November 2014 Clementia ... gegeben, dass die Europäische Arzneimittel-Agentur (European ... als Orphan-Medizinprodukt an Palovarotene vergeben hat, ... Behandlung von Fibrodysplasia ossificans progressiva (FOP). ... genetische Krankheit, die von schmerzhaften, wiederkehrenden ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... BioTrends Research Group, Inc. announces the release of the ... and Cimzia report. The survey was completed by ... qualitative interviews with a subset (n=20) of the survey respondents to ... employed to differentiate the products. Over the course of the ...
... , ATLANTA, Dec. 23 Alimera Sciences, Inc., a privately ... commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from ... The FAME Study consists of two Phase 3 pivotal clinical ... Iluvien in the treatment of diabetic macular edema (DME). The ...
Cached Medicine Technology:Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 2Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
(Date:11/23/2014)... 23, 2014 Locks-Magnetic.com, a notable magnetic ... Moreover, all the new products are available at low ... manager is proud of the new emergency doors. The ... And customers can choose from several colors. All of ... quality emergency door release is not as easy as ...
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity doctor ... was recently featured on International Business Times. ... of American Medical Aesthetics & Wellness, also known as ... scholarship to attend an M.D./Ph.D program at University of ... of Chicago, where his field of study was neuro-biochemistry. ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... City, Utah (PRWEB) November 23, 2014 ... health insurance reimbursement for small businesses, announced their ... book, The End of Employer-Provided Health Insurance. ... insurance is the greatest financial risk facing most ... facing U.S. employers, small and large, when it ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... active may help to tackle health threats, study says ... large body size, former professional football players aren,t at ... that looked at 201 retired NFL players. , The ... group of men from the population-based Dallas Heart Study ...
... -- The angiotensin system inhibitor irbesartan did not improve outcomes ... left ventricular ejection fraction. -- ... predominantly affects women and older patients; ... therapies is critical. NEW ORLEANS, Nov. 11 An angiotensin ...
... prevention trial on low-dose aspirin in diabetics,Japanese investigators report ... preventing the primary endpoints of all atherosclerotic events,although it ... - Low-dose aspirin was also associated with a reduced ... a subgroup of diabetics who,were over age 65., ...
... highlights:, -- Individually tailored doses of ... month as measured by platelet reactivity,monitoring by ... measures a,patient,s anti-platelet response to clopidogrel., ... bleeding events,between treatment and control groups., ...
... Study highlights:, - In a randomized, double-blind study ... C-reactive protein (hsCRP) greater than or equal to,2, those ... 31 heart attacks,and 33 strokes compared to 68 and ... analysis showed similar findings across gender, race,ethnicity and Framingham ...
... N.J., Nov. 11, 2008) The F.M. Kirby Foundation of ... Nursing at Rutgers, The State University of New Jersey, to ... Jersey residents. , The grant will also fund the work ... and service in the best academic tradition, said Interim Dean ...
Cached Medicine News:Health News:Retired NFL Players Don't Face Greater Heart Risk 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 2Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 4Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 2Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 2Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 4Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 5
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: